Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 10:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Elevated Blood Glucose Clear all
Completed No phase listed Observational

Accuracy of Hemoglobin A1C to Predict Glycemia in HIV

NCT00433628
View directory record Official record
Conditions
HIV, Diabetes, Hyperglycemia
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers

NCT01128192
View directory record Official record
Conditions
Hyperglycemia
Interventions
pasireotide
Drug
Lead sponsor
Robert R. Henry, MD
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Early Phase 1 Interventional

Prospective Study of Personalized Approach to Inpatient Patients With Hyperglycemia

NCT03904199
View directory record Official record
Conditions
Hyperglycemia
Interventions
Insulin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2023 · Synced Jul 24, 2026, 10:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Phase 1 Interventional

The Metabolic Effects of Almond Consumption in Adults With Pre-Diabetes

NCT00270985
View directory record Official record
Conditions
Prediabetes, Insulin Resistance, Metabolic Syndrome
Interventions
Almonds in a calorie controlled diet, Nut free diet
Behavioral
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 21, 2016 · Synced Jul 24, 2026, 10:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform

NCT05121844
View directory record Official record
Conditions
Weight Loss, Metabolic Syndrome, Pre-diabetes, Central Obesity, Glucose Intolerance, Metabolic Glucose Disorders
Interventions
Continuous Glucose Monitor Device
Device
Lead sponsor
Signos Inc
Industry
Eligibility
18 Years and older
Enrollment
31,187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 24, 2026, 10:56 AM EDT
Terminated Phase 4 Interventional Results available

Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients

NCT03743025
View directory record Official record
Conditions
Stress Hyperglycemia
Interventions
Dulaglutide Injection, Saline Injection
Drug · Other
Lead sponsor
Emory University
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Jul 24, 2026, 10:56 AM EDT
Withdrawn Not applicable Interventional

CGM/Clarity Use, Glycemic Control and Clinical Outcomes

NCT03827434
View directory record Official record
Conditions
Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions
Continuous glucose Monitoring Devices and Clarity Software, Point of Care (POC) blood glucose
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 24, 2026, 10:56 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

NCT01803711
View directory record Official record
Conditions
Major Depression, Cancer, Diabetes, Cardiovascular Diseases
Interventions
Desvenlafaxine, Omega 3 Fatty acids, Placebo (for Omega 3 fatty acid supplement)
Drug · Dietary Supplement
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Jul 24, 2026, 10:56 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

The TCF7L2 Gene: Dietary Prevention of T2DM

NCT03458494
View directory record Official record
Conditions
Type2 Diabetes, Glucose, High Blood
Interventions
Mediterranean Diet, Low-fat diet
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Not applicable Interventional

Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence

NCT01932866
View directory record Official record
Conditions
Pre-diabetes, Diabetes Risk Score, Motivation
Interventions
diabetic risk score
Other
Lead sponsor
59th Medical Wing
Federal
Eligibility
30 Years to 75 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Travis AFB, California • Andrews Air Force Base, Maryland • Nellis Air Force Base, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Jul 24, 2026, 10:56 AM EDT
Recruiting No phase listed Observational

Type 1 Diabetes Extension Study

NCT02734277
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, T1DM, T1D
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
12
States / cities
San Francisco, California • Stanford, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate and Study Drug Levels in Blood Plasma When Giving High Doses of GSK189075 to Healthy Volunteers

NCT00501930
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Early Phase 1 Interventional

Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy

NCT01945099
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ePID closed loop system, hyaluronidase, Lispro-PH20
Device · Drug
Lead sponsor
Yale University
Other
Eligibility
12 Years to 40 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Phase 2 Interventional Results available

Safety & Effectiveness on Vascular Structure and Function of ACZ885 in Atherosclerosis and Either T2DM or IGT Patients

NCT00995930
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Atherosclerosis, Prediabetic State
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 74 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Not applicable Interventional

Effects of Capros in Patients With Type-1 Diabetes

NCT02634216
View directory record Official record
Conditions
Type I Diabetes
Interventions
Capros
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
10 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Jul 24, 2026, 10:56 AM EDT
Recruiting Phase 2 Interventional

Long Term Impact of Time-Restricted Eating on Parameters of Cardiometabolic Health

NCT07189234
View directory record Official record
Conditions
Metabolic Syndrome, Pre-diabetes
Interventions
Time-restricted eating (TRE) + Standard of Care, Standard of Care
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 24, 2026, 10:56 AM EDT
Active, not recruiting No phase listed Observational

Dilapan-S®: A Multicenter US E-registry

NCT04451109
View directory record Official record
Conditions
Post Term Pregnancy, Premature Rupture of Membrane, Fetal Growth Retardation, Oligohydramnios, Gestational Diabetes, High Blood Pressure in Pregnancy
Interventions
Dilapan-S
Device
Lead sponsor
Medicem Technology s.r.o.
Other
Eligibility
18 Years and older · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Jul 24, 2026, 10:56 AM EDT
Enrolling by invitation Phase 2 Interventional Accepts healthy volunteers

Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.

NCT03389100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Pre-diabetes
Interventions
18F-MK6240 injection
Drug
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 69 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 24, 2026, 10:56 AM EDT
Active, not recruiting Not applicable Interventional

Circadian Health Regulation and Optimization for Rejuvenation Outcomes

NCT07203196
View directory record Official record
Conditions
Aging, Healthy, Blood Sugar; High, Blood Sugar (Glucose) Control, Time Restricted Eating, Circadian Dysregulation
Interventions
Circadian Rhythm Optimization
Behavioral
Lead sponsor
Salk Institute for Biological Studies
Other
Eligibility
50 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Phase 3 Interventional Results available

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone

NCT00763815
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Lixisenatide (AVE0010), Placebo, Pen auto-injector, Pioglitazone, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Jul 24, 2026, 10:56 AM EDT
Withdrawn Not applicable Interventional

Isoleucine Addition Treatment Effects in a Controlled Diet Study

NCT07329088
View directory record Official record
Conditions
Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Metabolic Syndrome (MetS), Obesity & Overweight
Interventions
L-Isoleucine, Low-isoleucine diet
Dietary Supplement · Other
Lead sponsor
Jean L. Fry
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Phase 4 Interventional Results available

Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes

NCT01845831
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Sitagliptin, Basal Bolus, Metformin and Sitagliptin, Glargine, Glargine 50%, Glargine 80%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 24, 2026, 10:56 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Feasibility Study Assessing The Ability Of An Insulin Pump-Controlling Algorithm To Minimize Hypoglycemia And Hyperglycemia In Patients With Type 1 Diabetes In A Clinical Research Setting

NCT01401751
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Hypoglycemia-Hyperglycemia Minimizer System
Device
Lead sponsor
Animas Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 24, 2026, 10:56 AM EDT